ArticleGastroenterology2019
Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States.
Article in Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05374980 (The Effects of Fermented Milk Product With Probiotic on Helicobacter Pylori Infection, Gut Microbiome and Metabolism.), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Fermented Milk Product With Probiotic on Helicobacter Pylori Infection, Gut Microbiome and Metabolism.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Is flexible sigmoidoscopy screening associated with reducing colorectal cancer incidence and mortality? a meta-analysis and systematic review.Frontiers in oncology · 2023Pooled it
- Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.Nature medicine · 2024Trial
- Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.BMC gastroenterology · 2023Trial
- Effects ofBMJ (Clinical research ed.) · 2019Trial
- The Role of Computational Models in the Detection of Colorectal Carcinoma and Precancerous Lesions.International journal of molecular sciences · 2026Review
- Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.Journal of gastroenterology and hepatology · 2026Article
- Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts.Blood cancer journal · 2026Article
- Beyond the Stomach: Exploring the Role ofExpert reviews in molecular medicine · 2026Review
- Screening of putative inhibitors for cytotoxin VacA from Helicobacter pylori.Scientific reports · 2026Article
- Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model.International journal of molecular sciences · 2026Review
- Zn-Quer Nanozymes Reprogram the Malignant Phenotypic Transformation of Gastric Cancer Cells via Cascade Reactive Oxygen Species Coordination.ACS applied materials & interfaces · 2026Article
- Global and regional burden of colorectal cancer potentially related to Helicobacter pylori exposure: a risk attribution modelling study.eGastroenterology · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- The microbiome in cancer.iMeta · 2025Review
- Helicobacter pylori, peptic ulcer disease, and colorectal cancer: a prospective study with genome-wide interaction analysis and Mendelian randomization.Infectious agents and cancer · 2025Article
- High Seroprevalence ofGastroenterology research · 2025Article
- Article
- Beyond the stomach: the association betweenFrontiers in cellular and infection microbiology · 2025Review
- Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship toFrontiers in oncology · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byReply.2019
Authors and funding
28 authors at 15 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsPrevious studies reported an association of the bacteria Helicobacter pylori, the primary cause of gastric cancer, and risk of colorectal cancer (CRC). However, these findings have been inconsistent, appear to vary with population characteristics, and may be specific for virulence factor VacA. To more thoroughly evaluate the potential association of H pylori antibodies with CRC risk, we assembled a large consortium of cohorts representing diverse populations in the United States.
methodsWe used H pylori multiplex serologic assays to analyze serum samples from 4063 incident cases of CRC, collected before diagnosis, and 4063 matched individuals without CRC (controls) from 10 prospective cohorts for antibody responses to 13 H pylori proteins, including virulence factors VacA and CagA. The association of seropositivity to H pylori proteins, as well as protein-specific antibody level, with odds of CRC was determined by conditional logistic regression.
resultsOverall, 40% of controls and 41% of cases were H pylori-seropositive (odds ratio [OR], 1.09; 95% CI, 0.99-1.20). H pylori VacA-specific seropositivity was associated with an 11% increased odds of CRC (OR, 1.11; 95% CI, 1.01-1.22), and this association was particularly strong among African Americans (OR, 1.45; 95% CI, 1.08-1.95). Additionally, odds of CRC increased with level of VacA antibody in the overall cohort (P = .008) and specifically among African Americans (P = .007).
conclusionsIn an analysis of a large consortium of cohorts representing diverse populations, we found serologic responses to H pylori VacA to associate with increased risk of CRC risk, particularly for African Americans. Future studies should seek to understand whether this marker is related to virulent H pylori strains carried in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.